Published online before print August 25, 2005, doi: 10.1161/01.ATV.0000183937.65887.9c
© 2005 American Heart Association, Inc.
Thrombosis |
Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?
Evidence from a Meta-Analysis of Genetic Association Studies
From the Department of Social Medicine, Bristol, UK.
Correspondence to George Davey Smith, Department of Social Medicine, Canynge Hall, Whiteladies Rd, Bristol BS8 2PR, United Kingdom. E-mail zetkin{at}bristol.ac.uk
Objective— The purpose of this study was to assess whether a genetic variant associated with higher fibrinogen levels is associated with increased coronary heart disease (CHD) risk, as a test of the causal influence of fibrinogen on CHD.
Methods and Results— We performed a meta-analysis of case-control and prospective studies of the G-455
A and C-148T ß-fibrinogen promoter region variants, in relation to CHD risk. The 19 studies found included 12,393 cases and 21,649 controls. Fibrinogen levels were robustly related to the genetic variants (mean increase per allele, 0.117 g/L; 95% CI, 0.091–0.142 g/L). However, the genetic variants were unrelated to CHD risk (odds ratio per allele, 0.976; 95% CI, 0.916–1.040). The predicted causal odds ratio for a 1 g/L higher plasma fibrinogen level, given the genetic variant–fibrinogen and genetic variant–CHD associations, was 0.81 (95% CI, 0.46–1.40).
Conclusions— Although imprecise, the predicted causal effect of fibrinogen on CHD is clearly different from the odds ratio of 1.8 (95% CI, 1.6–2.0) for an increase of 1 g/L derived from a meta-analysis of observational studies. This evidence suggests that lowering the fibrinogen level may not, in itself, reduce CHD risk.
Observational studies demonstrate that circulating fibrinogen levels are associated with increased coronary heart disease risk. However, in a meta-analysis of studies that relate genetic variants associated with differences in fibrinogen level to coronary heart disease risk, we find no association. These data suggest that fibrinogen is not a cause of increased coronary heart disease risk.
Key Words: Mendelian randomization • fibrinogen • coronary heart disease
This article has been cited by other articles:
 |
|
 |
|
  F. Drenos, P. J. Talmud, J. P. Casas, L. Smeeth, J. Palmen, S. E. Humphries, and A. D. Hingorani Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk Hum. Mol. Genet., June 15, 2009; 18(12): 2305 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target? Clin. Chem., February 1, 2009; 55(2): 239 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kivimaki, G. D. Smith, N. J. Timpson, D. A. Lawlor, G. D. Batty, M. Kahonen, M. Juonala, T. Ronnemaa, J. S.A. Viikari, T. Lehtimaki, et al. Lifetime body mass index and later atherosclerosis risk in young adults: examining causal links using Mendelian randomization in the Cardiovascular Risk in Young Finns study Eur. Heart J., October 2, 2008; 29(20): 2552 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. A. Ioannidis Effect of Formal Statistical Significance on the Credibility of Observational Associations Am. J. Epidemiol., August 15, 2008; 168(4): 374 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, J. Biele, J. C. Mueller, A. Schomig, and A. Kastrati Fibrinogen Genes and Myocardial Infarction: A Haplotype Analysis Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Smith and S. Ebrahim Reply Int. J. Epidemiol., April 1, 2008; 37(2): 416 - 417. [Full Text] [PDF]
|
|
|
|
|
|
Associations of Plasma Fibrinogen Levels with Established Cardiovascular Disease Risk Factors, Inflammatory Markers, and Other Characteristics: Individual Participant Meta-Analysis of 154,211 Adults in 31 Prospective Studies: The Fibrinogen Studies Collaboration Am. J. Epidemiol., October 15, 2007; 166(8): 867 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P Casas, T. Shah, J. Cooper, E. Hawe, A. D McMahon, D. Gaffney, C. J Packard, D. S O'Reilly, I. Juhan-Vague, J. S Yudkin, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization Int. J. Epidemiol., August 1, 2006; 35(4): 922 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W Meade, S. E Humphries, and B. L De Stavola Commentary: Fibrinogen and coronary heart disease--test of causality by 'Mendelian' randomization by Keavney et al. Int. J. Epidemiol., August 1, 2006; 35(4): 944 - 947. [Full Text] [PDF]
|
|
|
|
|
|
B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, M. Delepine, M. Lathrop, R. Peto, R. Collins, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' Int. J. Epidemiol., August 1, 2006; 35(4): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mora, N. Rifai, J. E. Buring, and P. M Ridker Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events Circulation, August 1, 2006; 114(5): 381 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Smith, M. Gwinn, S. Ebrahim, L. J Palmer, and M. J Khoury Make it HuGE: human genome epidemiology reviews, population health, and the IJE Int. J. Epidemiol., June 1, 2006; 35(3): 507 - 510. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Smith Randomised by (your) god: robust inference from an observational study design J Epidemiol Community Health, May 1, 2006; 60(5): 382 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D.O. Lowe The association between elevated levels of inflammation biomarkers and coronary artery disease and death. Can. Med. Assoc. J., February 14, 2006; 174(4): 479 - 480. [Full Text] [PDF]
|
|